


REQUEST FOR ACCESS OF ABANDONED APPLICATION UNDER 37 CFR 1.14(a)



In re Application of

Application Number

08-256631

Filed

12-1-94

Group Art Unit

Examiner

Paper No.

116

Assistant Commissioner for Patents
Washington, DC 20231

I hereby request access under 37 CFR 1.14(a)(3)(iv) to the application file record of the above-identified ABANDONED application, which is: (CHECK ONE)

- ☐ (A) referred to in United States Patent Number 5871734, column _____
- ☐ (B) referred to in an application that is open to public inspection as set forth in 37 CFR 1.11, i.e., Application No. _____, filed _____, on page _____ of paper number _____
- ☐ (C) an application that claims the benefit of the filing date of an application that is open to public inspection, i.e., Application No. _____, filed _____, or
- ☐ (D) an application in which the applicant has filed an authorization to lay open the complete application to the public.

Please direct any correspondence concerning this request to the following address:

Nettie Walker

Signature

N. WALKER

Typed or printed name

Date

3-29-00

FOR PTO USE ONLY

Approved by:

[Signature]
(initials)
FTU

Unit:

[54] TREATMENT FOR ASTHMA WITH VLA-4
BLOCKING AGENTS

[75] Inventors: Roy R. Lobb, Westwood; Linda C.
Burkly, West Newton, both of Mass.

[73] Assignee: Biogen, Inc., Cambridge, Mass.

[21] Appl. No.: 822,830

[22] Filed: Mar. 21, 1997

Related U.S. Application Data

[63] Continuation of Ser. No. 456,193, May 31, 1995, abandoned, which is a continuation-in-part of Ser. No. 374,331, Jan. 18, 1995, abandoned, which is a continuation-in-part of Ser. No. 256,631, Dec. 1, 1994, abandoned, which is a continuation-in-part of PCT/US93/00030 Jan. 12, 1993, which is a continuation-in-part of Ser. No. 821,768, Jan. 13, 1992, abandoned.

[51] Int. Cl.⁶ A61K 39/395; A61K 35/12;
A61K 38/17

[52] U.S. Cl. 424/144.1; 424/130.1;
424/133.1; 424/171.1; 424/143.1; 424/153.1;
424/154.1; 424/173.1; 514/2; 514/8; 514/885

[58] Field of Search 424/130.1, 133.1,
424/143.1, 154.1; 514/387.1, 388.22; 514/2,
8

[56] References Cited

U.S. PATENT DOCUMENTS

4,816,397 3/1989 Boss et al. .
4,833,092 5/1989 Geysen .
5,116,964 5/1992 Capon .
5,272,263 12/1993 Heshon .
5,730,978 3/1998 Wayner et al. .

FOREIGN PATENT DOCUMENTS

0 330 506 8/1989 European Pat. Off. .
387701 9/1990 European Pat. Off. .
9103252 3/1991 WIPO .
WO 92/00751 1/1992 WIPO .
WO 95/19790 1/1995 WIPO .

OTHER PUBLICATIONS

McNeil JNCI 87: 1658-1660 (1995).
Issekutz et al. J. Immunol. 147: 109-116 (1991).
Issekutz J. Immunol. 147: 4178-4184 (1991).
Mountain et al. Gen Eng Rev 110:1, 10-13 only (1992).
Edgington Biotechnology 10: 383-389 (1992).
Ward et al. Therapeutic Immunology 1: 165-171 (1994).
McCabe et al. Cell Immunol. 150: 364-375 (1993).
Paul Fundamental Immunol. 3rd Ed. 1993 Raven Press p.
242 only.
Osborn Cell 62: 3-6 1990.
Gundel et al. J Allergy Clin. Immunol. 85: 282 (1990).
Altman, L.K., (1991) "Despite Gains in Treatment, Asthma
Worsens", *New York Times*, The Doctor's World, Mar. 26.
Weller, P.F., et al., (1991) "Human eosinophil adherence to
vascular endothelium mediated by binding to vascular cell
adhesion molecule 1 and endothelial leukocyte adhesion
molecule 1", *Proceedings of the National Academy of Sci-
ences*, vol. 88, pp. 7430-7433.

Walsh, G.M., et al., (1991) "Human Eosinophil, But Not
Neutrophil, Adherence to IL-1-Stimulated Human Umbili-
cal Vascular Endothelial Cells Is $\alpha_4\beta_1$ (Very Late Anti-
gen-4) Dependent", *J. Immunol.*, vol. 146, pp. 3419-3423.

Bochner, B.S., et al., (1991) "Adhesion of Human Baso-
phils, Eosinophils, and Neutrophils to Interleukin 1-acti-
vated Human Vascular Endothelial Cells: Contributions of
Endothelial Cell Adhesion Molecules", *J. Exp. Med.*, vol.
173, pp. 1553-1556.

Dobrina, A., et al., (1991) "Mechanisms of Eosinophil
Adherence to Cultured Vascular Endothelial Cells", *J. Clin.
Invest.*, vol. 88, pp. 20-26.

Pulido, R., et al., (1991) "Functional Evidence for Three
Distinct and Independently Inhibitable Adhesion Activated
Mediated by the Human Integrin VLA-4", *J. Biol. Chem.*,
vol. 266, No. 16, pp. 10241-10245.

Gundel, R.H., et al., (1991) "Endothelial Leukocyte Adhe-
sion Molecule-1 Mediates Antigen-induced Acute Airway
Inflammation and Late-phase Airway Obstruction in Mon-
keys", *J. Clin. Invest.*, vol. 88, pp. 1407-1411.

Parmentier, S., et al., (1991) "Role of Glycoprotein IIa (beta
subunit of very late activation antigens) in platelet func-
tions", *Chemical Abstract*, vol. 115, No. 23, Abst. # 252
791h.

Onish, R., et al., (1991) "A monoclonal antibody, 2H7,
which defines a new very late activation antigen, inhibits
IL-2-mediated cell proliferation", *Chemical Abstract*, vol.
114, No. 9, Abst. #79 730s.

Sears, M.R., (1990) "Epidemiology of Asthma", in *Asthma
as an Inflammatory Disease*, P. O'Byrne Ed., Marcel Dek-
ker, Inc.; New York, pp. 15-48.

Cockcroft, D.W., (1990) "Atopy and Asthma", in *Asthma as
an Inflammatory Disease*, P. O'Byrne Ed., Marcel Dekker,
Inc.; New York, pp. 103-125.

Cuss, F.M.C., (1990) "The Pharmacology of Antiasthma
Medications", in *Asthma as an Inflammatory Disease*, P.
O'Byrne Ed., Marcel Dekker, Inc.; New York, pp. 199-250.

O'Byrne, P.M., (1990) "Airway Inflammation and Asthma",
in *Asthma as an Inflammatory Disease*, P. O'Byrne Ed.,
Marcel Dekker, Inc.; New York, pp. 143-157.

Hogg, J.C., (1990) "Pathology of Asthma", in *Asthma as an
Inflammatory Disease*, P. O'Byrne Ed., Marcel Dekker, Inc.;
New York, pp. 1-13.

Chung, K.F., (1990) "Inflammatory Mediators in Asthma",
in *Asthma as an Inflammatory Disease*, P. O'Byrne Ed.,
Marcel Dekker, Inc.; New York, pp. 159-183.

(List continued on next page.)

Primary Examiner—Lila Feisee

Assistant Examiner—Phillip Gambel

Attorney, Agent, or Firm—Louis Myers, Esq.; Lahive &
Cockfield, LLP

[57] ABSTRACT

A method for the treatment of asthma is disclosed. The
method comprises administration of an antibody, polypep-
tide or other molecule recognizing VLA-4, a protein
expressed on the surface of certain leukocytes such as
eosinophils.

22 Claims, 12 Drawing Sheets